Environmental Public Health Commons^™

Why Public Health Agencies Cannot Depend On Good Laboratory Practices As A Criterion For Selecting Data: The Case Of Bisphenol A, John Peterson Myers, Frederick S. Vom Saal, Benson T. Akingbemi, Koji Arizono, Scott Belcher, Theo Colborn, Ibrahim Chahoud, D. Andrew Crain, Francesca Farabollini, Louis J. Guillette Jr., Terry Hassold, Shuk-Mei Ho, Patricia A. Hunt, Taisen Iguchi, Susan Jobling, Jun Kanno, Hans Laufer, Michele Marcus, John A. Mclachlan, Angel Nadal, Jörg Oehlmann, Nicolás Olea, Paola Palanza, Stefano Parmigiani, Beverly S. Rubin, Gilbert Schoenfelder, Carlos Sonnenschein, Ana M. Soto, Chris E. Talsness, Julia A. Taylor, Laura Vandenberg, John G. Vandenbergh, Sarah Vogel, Cheryl S. Watson, Wade V. Welshons, R. Thomas Zoeller

Laura Vandenberg

BACKGROUND: In their safety evaluations of bisphenol A (BPA), the U.S. Food and Drug Administration (FDA) and a counterpart in Europe, the European Food Safety Authority (EFSA), have given special prominence to two industry-funded studies that adhered to standards defined by Good Laboratory Practices (GLP). These same agencies have given much less weight in risk assessments to a large number of independently replicated non-GLP studies conducted with government funding by the leading experts in various fields of science from around the world. OBJECTIVES: We reviewed differences between industry-funded GLP studies of BPA conducted by commercial laboratories for regulatory purposes and …